Talecris Biotherapeutics Holdings Corp

Talecris Biotherapeutics Holdings Corp. is a biopharmaceutical company that is a producer and marketer of plasma-derived protein therapies in the world. The Company develops, produces, markets and distributes therapies that help people suffering from conditions, such as immune deficiency disorders, alpha-1 antitrypsin (AAT) deficiency, infectious diseases, hemophilia and severe burns. The Company’s largest product, Gamunex Immune Globulin Intravenous (Human), is one of the products in the intravenous immune globulin (IGIV) market. Its second largest product, Prolastin Alpha 1 Proteinase Inhibitor (Human), was granted orphan drug status and has a 71% share of sales in the United States, a 78% share of sales in the European Union and brand recognition within the alpha-1 proteinase inhibitor (A1PI) category. In June 2007, it acquired three additional plasma collection centers from International BioResources, L.L.C. (IBR).